NCT04869124 - Dapagliflozin on Volume Vascular Outcomes. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 15, 2021

Primary Completion Date

September 26, 2024

Study Completion Date

October 28, 2024

Conditions

Heart Failure，Congestive

Interventions

DRUG

Dapagliflozin

Dapagliflozin propanediol (FORXIGA) tablet: 10 mg once daily p.o. on top of recommended standard therapy, duration of administration: 12 weeks.

DRUG

Placebo

Placebo tablet, matching Dapagliflozin, once daily p.o. on top of recommended standard therapy, duration of administration: 12 weeks.

Trial Locations (1)

University Heart Center Zurich, Zurich